entertainment -WSS

entertainment

author：explore 2025-09-30 01:13:11 - browse：46

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Victims of gun violence feel impacts long after bullet wound

explore

WSS

Stem cell clinics for heart failure: buyer be wary

Stem cell clinics for heart failure: buyer be wary

The drug industry sees a key ally in the Senate prevail

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

STAT Executive Editor Rick Berke on STAT's 8th birthday

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

hotspot

entertainment

explore

Tori Bowie and the unacceptable rates of Black maternal death

Dramatically reducing cancer deaths requires the PASTEUR Act

At least 13 dead in Texas as scorching temps continue

White House drug shortage group privately met with industry

Activists slam private health insurers over coverage restrictions

Excited delirium, Elijah McClain, and emergency physicians

Malaria cases in Florida and Texas: Here’s what you need to know

MoonLake credibility takes another hit with mid

Cancer drug shortages should be causing more outrage

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

hotspot

Verily hires former Apple Health leader as chief scientific officer

Diversify hospital leadership teams to protect BIPOC patient health

Sanofi CEO defends move to abandon profit guidance, boost research

What Mike Pence has said that could be used in a Donald Trump trial

Biotech incubator Curie.Bio graduates its first startup

MoonLake credibility takes another hit with mid

focus

focus

explore

hotspot